RF Acquisition 株価情報 (NASDAQ: RFACU)

最新ニュース RF Acquisition (NASDAQ:RFACU) 株価情報

RF Acquisition Corp is a blank check company.

RF Acquisition Corp

Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) reported quarterly earnings of $6.53 per share which beat the analyst consensus estimate of $6.02 by 8.47 percent. This is a 4.81 percent decrease over earnings of $6.86 per share from the same period last year. The company reported quarterly sales of $524.20 million which missed the analyst consensus estimate of $530.55 million by 1.20 percent. This is a 4.28 percent increase over sales of $502.70 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

Affiliated Managers Group Q4 Adj EPS $6.53 Beats $6.02 Estimate, Sales $524.20M Miss $530.55M Estimate

Guidance

APTV

Aptiv Expects FY25 Net Sales Of $19.6B - $20.4B (Est $19.96B), Adj EPS Of $7.00 - $7.60 (Est $6.92)

Benchmark analyst Cody Acree reiterates Skyworks Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) from Hold to Hold.

Reiteration

Analyst Ratings

SWKS

Benchmark Reiterates Hold on Skyworks Solutionsto Hold

Guidance for 2025
The following guidance assumes foreign exchange rates effective as of December&nbsp;31, 2024, for the full year. Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="5" rowspan="1">(Dollars in billions, except per share data)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Results</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">2025 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Low</td>
<td colspan="1" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Labcorp Enterprise (1)(2)</td>
<td colspan="1" rowspan="1">$13.01</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.7&nbsp;%</td>
<td colspan="1" rowspan="1">8.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diagnostics Laboratories (3)</td>
<td colspan="1" rowspan="1">$10.14</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">6.5&nbsp;%</td>
<td colspan="1" rowspan="1">7.7&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Biopharma Laboratory Services (4)</td>
<td colspan="1" rowspan="1">$2.92</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">3.0&nbsp;%</td>
<td colspan="1" rowspan="1">5.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$14.57</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$15.60</td>
<td colspan="1" rowspan="1">$16.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow</td>
<td colspan="1" rowspan="1">$1.10</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.10</td>
<td colspan="1" rowspan="1">$1.25</td>
</tr>
</tbody>
</table>
</figure>

Health Care

General

Laboratory Corporation Of America Holdings

Labcorp Expects 2025 Sales Of $13.88B-$14.05B Versus Consensus Of $13.79B, and Adjusted EPS Of $15.60-$16.40 Versus Consensus Of $16.02

Barclays analyst Adrienne Yih maintains Capri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) with a Equal-Weight and lowers the price target from $21 to $19.

Price Target

CPRI

Barclays Maintains Equal-Weight on Capri Holdings, Lowers Price Target to $19

WIIM

Hershey shares are trading lower after the company reported Q4 financial results and issued weaker-than-expected FY25 outlook.

Aptiv Expects Q1 Net Sales Of $4.635B - $4.835B (Est $4.811B), Adj EPS Of $1.40 - $1.60 (Est $1.49)

Needham analyst James Ricchiuti maintains Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) with a Buy and lowers the price target from $182 to $130.

Needham Maintains Buy on Impinj, Lowers Price Target to $130

Skyworks Solutions Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) reported better-than-expected first-quarter, but issued second-quarter<a href="https://www.benzinga.com/quote/SWKS/earnings"> adjusted EPS guidance below estimates..</a>
Skyworks Solutions reported quarterly earnings of $1.60 per share which beat the analyst consensus estimate of $1.57 per share. The company reported quarterly sales of $1.068 billion which beat the analyst consensus estimate of $1.066 billion.
"Skyworks started the new fiscal year with solid results, growing revenue 4% sequentially and surpassing the midpoint of our guidance," said Liam Griffin, president and CEO of Skyworks.
"We have observed consistent improvement in demand indicators within Broad Markets, while we have successfully supported multiple new product launches in Mobile. Furthermore, we posted another quarter of impressive free cash flow with margins exceeding 30%."
For the second quarter, Skyworks said it expects second-quarter revenue to be between $935 million and $965 million versus estimates of $949.04 million, according to Benzinga Pro. The company anticipates second-quarter adjusted earnings of $1.20 per share versus estimates of $1.22 per share.
Skyworks shares gained 0.8% to close at $87.08 on Wednesday.
These analysts made changes to their price targets on Skyworks following earnings announcement.
<ul>
<li>Mizuho analyst Vijay Rakesh downgraded Skyworks from Outperform to Neutral and lowered the price target from $105 to $62.</li>
<li>B. Riley Securities analyst Craig Ellis downgraded Skyworks from Buy to Neutral and lowered the price target from $110 to $65.</li>
<li>Stifel analyst Ruben Roy downgraded Skyworks from Buy to Hold and lowered the price target from $105 to $62.</li>
</ul>
Considering buying SWKS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="606" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06064926/image-2-12-1024x606.png" alt="" class="wp-image-769160" style="width:657px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06064926/image-2-12-1024x606.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06064926/image-2-12-300x178.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06064926/image-2-12-768x455.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/06064926/image-2-12.png 1115w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43493237/jim-cramer-this-health-care-stock-is-a-winner-buy-bitcoin-instead-of-coinbase">Jim Cramer: This Health Care Stock Is A &#8216;Winner,&#8217; Buy Bitcoin Instead Of Coinbase</a></li>
</ul>

Markets

Trading Ideas

Skyworks Solutions Analysts Slash Their Forecasts Following Q1 Results

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) reported quarterly earnings of $3.45 per share which beat the analyst consensus estimate of $3.39 by 1.77 percent. This is a 4.55 percent increase over earnings of $3.30 per share from the same period last year. The company reported quarterly sales of $3.33 billion which beat the analyst consensus estimate of $3.31 billion by 0.63 percent. This is a 9.76 percent increase over sales of $3.03 billion the same period last year.

Laboratory Corp Q4 2024 Adj EPS $3.45 Beats $3.39 Estimate, Sales $3.33B Beat $3.31B Estimate

KVUE

Kenvue Sees FY25 Sales Growth Of (-1)% - +1%; Adj EPS Growth Of 0% - +2%

Advanced Drainage Systems Approved Quarterly Cash Dividend Of $0.16 Per Share, A 14% Increase Over The Prior Year Dividend Amount; Dividend Is Payable On  March 14

The Board of Directors of CMS Energy today increased the quarterly dividend on the company's common stock to 54.25 cents per share, up from 51.50 cents per share.&nbsp;
Based on Wednesday's closing price for CMS Energy common stock, $67.12, the dividend represents an annualized yield of 3.2 percent.
The first quarter dividend for the common stock (CUSIP: 125896100) is payable Feb. 28, 2025, to shareholders of record Feb. 17, 2025.

Dividends

CMS Energy Increases Quarterly Dividend To 54.25 Cents From 51.50 Cents Per Share, Payable February 28

2025 Full-Year Financial Outlook Summary The company expects net sales growth of at least 2%, driven primarily by net price realization. Reported earnings per share is expected to be down in the high-40% range as higher commodity costs, rebased incentive compensation, and a higher economic tax rate are expected to more than offset price realization, productivity and cost savings programs.&nbsp; The company projects adjusted earnings per share to be down in the mid-30% range when excluding one-time costs associated with cost savings initiatives and acquisition integration activities.&nbsp; The gap between the reported and adjusted earnings per share growth outlooks primarily reflects a large derivative mark-to-market gain recorded in reported earnings per share in 2024.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">2025 Full-Year Outlook</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Total Company</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net sales growth4</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">At least 2%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Reported earnings per share growth</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Down high-40% range</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted earnings per share growth</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Down mid-30% range</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">4 The impact of the Sour Strips acquisition is anticipated to be an approximate 30 basis point benefit to net sales growth for the full-year 2025. Additionally, the impact of foreign currency exchange rates is anticipated to be an approximate 30 basis point headwind to net sales growth for the full-year 2025.</td>
</tr>
</tbody>
</table>
</figure>
The company also expects:
<ul>
<li>A reported and adjusted effective tax rate in the range of approximately 14% to 15%;</li>
<li>Other expense, which primarily reflects the write-down of equity investments that qualify for a tax credit, of approximately $170 million to $180 million;</li>
<li>Interest expense of approximately $190 million to $195 million, reflecting a higher interest rate environment;</li>
<li>Capital expenditures of approximately $425 million to $450 million, as capital spending as a percentage of sales returns to historical levels; and</li>
<li>Advancing Agility &amp; Automation Initiative savings of approximately $125 million.</li>
</ul>

Hershey Sees FY2025 GAAP EPS $5.54-$5.86 vs $7.80 Est

Leerink Partners analyst Puneet Souda downgrades Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) from Outperform to Market Perform and lowers the price target from $80 to $75.

Downgrades

HOLX

Leerink Partners Downgrades Hologic to Market Perform, Lowers Price Target to $75

Advanced Drainage Systems Reiterates FY25 Net Sales Outlook Of $2.90B-$2.975B Vs. $2.93B Estimate

GOOS

Canada Goose Lowers FY25 Non-IFRS Adj. EBIT Margin Guidance From +60 Basis Points To -60 Basis Points To Range Of Flat To -100 Basis Points; Lowered Non-IFRS Adj. EPS Growth Guidance From Mid-Single Digit Increase To Low-Single Digit Increase To Flat

Hershey Sees FY2025 Adj EPS $6.00-$6.18 vs $7.36 Est

Needham analyst Quinn Bolton maintains SiTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SITM#NASDAQ">SITM</a>) with a Buy and raises the price target from $225 to $250.

SITM

Needham Maintains Buy on SiTime, Raises Price Target to $250

Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) reported quarterly adjusted earnings of $0.26 per share which met the analyst consensus estimate. This is a 16.13 percent decrease over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $3.66 billion which missed the analyst consensus estimate of $3.77 billion by 2.75 percent. This is a 0.11 percent decrease over sales of $3.67 billion the same period last year.

Comments

RF Acquisition

ニュース

最新ニュース RF Acquisition (NASDAQ:RFACU) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル